Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. In particular, Dr. Angiolillo has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies, for which he has received numerous national and international academic recognitions. Amongst these he has received the 2013 Outstanding Achievement Award from the European Society of Cardiology and for 7 consecutive years (since 2014) he has been in the top 1 percent of most-cited researchers worldwide according to Clarivate Analytics (formerly Thomson Reuters’ list of The World’s Most Influential Scientific Minds). He has also been a key investigator in the clinical development of numerous novel antithrombotic agents, working along slide with drug regulating agencies in the United States (FDA) and Europe (EMA), towards approval of these drugs and product labeling updates. His success in obtaining extramural funding (>$25 million) has allowed to develop one of the most active clinical research centers in the United States as well as one of the leading centers for thrombosis research in the world.